William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importan
Local impact of the NHMRC early breast cancer guidelines: where to from here? Med. J. Aust., vol. 167, p. 362-365, 1997.Local impact of the NHMRC early breast cancer guidelines: where to go from here? Med J Aust - JE, Boyages, et al....
SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol. 2015;17(12). doi:10.1007/s12094-015-1427-3.M, et al. SEOM clinical guidelines in early-stage breast cancer 2015. Clin TranslJ.A. Garcia-Saenz, B. Bermejo, L.G. Estevez, A.G. Palomo, X. Gonzalez-Farre...
of the esmo Guidelines Working Group Locally recurrent or metastatic breast cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. ... F Cardoso,N Harbeck,L Fallowfield,... - 《Annals of Oncology》 被引量: 749发表: 2012年 Chronic lymphocytic leukemia: ESMO Clinical Pr...
Breast Cancer in the Elderly: Retrospective Study on Diagnosis and Treatment According to National Guidelines Abstract: We set out to investigate the level of accordance of diagnosis and treatment of elderly breast cancer patients with national guidelines and t... ME Hamaker,WH Schreurs,JM Uppel...
Local impact of the NHMRC early breast cancer guidelinesBreast NeoplasmsConsumer Advocacy乳腺肿瘤消费者辩护Comment on Med J Aust. 1998 Feb 2;168(3):141.doi:10.5694/j.1326-5377.1998.tb141432.xM J, TurnerMed J AustMedical Journal of Australia...
Both incidence of breast cancer and survival have increased in recent years and there is a need to review follow up strategies. This study aims to assess the evidence for benefits of follow-up in different settings for women who have had treatment for early breast cancer. Method A systematic ...
new rules, women with dense breasts will receive a written memo alerting them that their status "makes it harder to find breast cancer." Those patients will also be directed to speak with their doctor about their results and whether they should receive additional screening to loo...
However, American Society of Clinical Oncology breast cancer surveillance guidelines suggest physician office visits every 3-6 months for 3 years, followed by visits every 6-12 months for 2 years, then annually. Women taking aromatase inhibitors should also undergo bone mineral density measurement ...
Concordance with NCCN treatment guidelines: relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis. Cancer. 2018;124(21):4231–40. https://doi.org/10.1002/cncr.31694. Article CAS PubMed Google Scholar Zhao B, Tsai C, Hunt KK, Blair ...